1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Lilly To Deliver More Proof Points In Obesity, Keep Building Pipeline In 2024

Zepbound Readouts Expected In Co-Morbidities

 
• By Mandy Jackson

Research head Dan Skovronsky said it’s hard to improve upon tirzepatide, but Lilly is advancing early and late-stage obesity drugs while investigating internal and external assets in weight loss and beyond.

Lilly San Diego
Lilly will have readouts in obesity-related diseases for Zepbound in 2024 • Source: Shutterstock

Eli Lilly and Company’s obesity pipeline had a standout year in 2023 that will be hard to top in 2024, but the drug maker will continue delivering data to show the impact that significant weight loss with GLP-1/GIP agonist tirzepatide can have on related co-morbidities. And while the company awaits Phase III results from its next-generation obesity medicines retatrutide and orforglipron in 2025, it continues to scour the biopharmaceutical landscape for additional drug candidates.

Key Takeaways

  • Lilly will focus on its Zepbound launch and additional readouts for the obesity drug in 2024 while advancing its next-generation weight loss medicines.

  • The company is also investigating additional new obesity medicines to stay ahead of competitors with novel drug candidates in the space

“For the most part, I would say it’s very challenging to improve upon a medicine like tirzepatide,” Lilly Research Laboratories president Dan Skovronsky said in an interview with Scrip during this month’s J.P. Morgan Healthcare Conference

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

More from Conferences

Balance And Focus Suggested For Globalizing Chinese Firms Amid Ongoing Uncertainties

 
• By Xu Hu

Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.

Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering

 
• By Alaric DeArment

Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 
• By Jessica Merrill

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.